{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidiqswvlf3unrka4vi2id6ltr4fhid3wnemgevhwyhzgpywpr75te",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mhedpexotgg2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiegww6gir5y45kjoqvz2jbfblmul62jbx6ne4qcokqkfqbjlxuooy"
    },
    "mimeType": "image/jpeg",
    "size": 135721
  },
  "path": "/news/2026-03-combination-treatment-benefits-patients-advanced.html",
  "publishedAt": "2026-03-18T16:00:04.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.",
  "title": "Combination treatment benefits patients with advanced breast cancer that has spread to the brain"
}